NZ505994A - Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases - Google Patents
Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseasesInfo
- Publication number
- NZ505994A NZ505994A NZ505994A NZ50599498A NZ505994A NZ 505994 A NZ505994 A NZ 505994A NZ 505994 A NZ505994 A NZ 505994A NZ 50599498 A NZ50599498 A NZ 50599498A NZ 505994 A NZ505994 A NZ 505994A
- Authority
- NZ
- New Zealand
- Prior art keywords
- statin
- matrix metalloproteinase
- vascular diseases
- metalloproteinase inhibitor
- treating vascular
- Prior art date
Links
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 208000019553 vascular disease Diseases 0.000 title 1
- 229940124761 MMP inhibitor Drugs 0.000 abstract 2
- -1 carboxyalkyl ketone Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000002923 oximes Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7826598P | 1998-03-17 | 1998-03-17 | |
| PCT/US1998/024681 WO1999047138A1 (en) | 1998-03-17 | 1998-11-20 | Statin-matrix metalloproteinase inhibitor combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ505994A true NZ505994A (en) | 2003-10-31 |
Family
ID=22142950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ505994A NZ505994A (en) | 1998-03-17 | 1998-11-20 | Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1063991A1 (https=) |
| JP (1) | JP2002506818A (https=) |
| KR (1) | KR20010041916A (https=) |
| AR (1) | AR018113A1 (https=) |
| AU (1) | AU1591699A (https=) |
| BR (1) | BR9815745A (https=) |
| CA (1) | CA2309588A1 (https=) |
| CO (1) | CO5070670A1 (https=) |
| GT (1) | GT199900039A (https=) |
| HN (1) | HN1999000029A (https=) |
| MY (1) | MY140504A (https=) |
| NZ (1) | NZ505994A (https=) |
| PA (1) | PA8469001A1 (https=) |
| PE (1) | PE20000348A1 (https=) |
| SV (1) | SV1999000026A (https=) |
| UY (1) | UY25436A1 (https=) |
| WO (1) | WO1999047138A1 (https=) |
| ZA (1) | ZA992106B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| RU2410118C2 (ru) | 2004-12-15 | 2011-01-27 | Зольвай Фармасьютиклз Гмбх | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ |
| CA2627599A1 (en) * | 2005-11-08 | 2007-05-18 | Ranbaxy Laboratories Limited | Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt |
| WO2010005389A1 (en) * | 2008-07-11 | 2010-01-14 | Forskarpatent I Syd Ab | Oxidized ldl specific antibody-fusion and conjugated proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016184A1 (en) * | 1995-11-02 | 1997-05-09 | Warner-Lambert Company | Method and pharmaceutical composition for regulating lipid concentration |
| NZ332711A (en) * | 1996-05-17 | 2000-06-23 | Warner Lambert Co | Biphenylsulfonylamino carboxylic acid derivatives as matrix metalloproteinase inhibitors |
| CA2263886A1 (en) * | 1996-12-09 | 1998-06-18 | Warner-Lambert Company | Method for treating and preventing heart failure and ventricular dilatation |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. |
-
1998
- 1998-11-20 BR BR9815745-0A patent/BR9815745A/pt not_active Application Discontinuation
- 1998-11-20 AU AU15916/99A patent/AU1591699A/en not_active Abandoned
- 1998-11-20 JP JP2000536378A patent/JP2002506818A/ja active Pending
- 1998-11-20 KR KR1020007010223A patent/KR20010041916A/ko not_active Ceased
- 1998-11-20 WO PCT/US1998/024681 patent/WO1999047138A1/en not_active Ceased
- 1998-11-20 EP EP98960279A patent/EP1063991A1/en not_active Withdrawn
- 1998-11-20 NZ NZ505994A patent/NZ505994A/xx unknown
- 1998-11-20 CA CA002309588A patent/CA2309588A1/en not_active Abandoned
-
1999
- 1999-02-24 AR ARP990100751A patent/AR018113A1/es unknown
- 1999-03-15 MY MYPI99000951A patent/MY140504A/en unknown
- 1999-03-16 CO CO99016109A patent/CO5070670A1/es unknown
- 1999-03-16 GT GT199900039A patent/GT199900039A/es unknown
- 1999-03-16 PE PE1999000217A patent/PE20000348A1/es not_active Application Discontinuation
- 1999-03-16 UY UY25436A patent/UY25436A1/es not_active Application Discontinuation
- 1999-03-16 PA PA19998469001A patent/PA8469001A1/es unknown
- 1999-03-16 HN HN1999000029A patent/HN1999000029A/es unknown
- 1999-03-16 ZA ZA9902106A patent/ZA992106B/xx unknown
- 1999-03-16 SV SV1999000026A patent/SV1999000026A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HN1999000029A (es) | 1999-09-29 |
| CO5070670A1 (es) | 2001-08-28 |
| GT199900039A (es) | 2000-09-06 |
| PE20000348A1 (es) | 2000-05-22 |
| ZA992106B (en) | 1999-09-30 |
| PA8469001A1 (es) | 2002-09-17 |
| BR9815745A (pt) | 2000-11-14 |
| EP1063991A1 (en) | 2001-01-03 |
| WO1999047138A1 (en) | 1999-09-23 |
| CA2309588A1 (en) | 1999-09-23 |
| MY140504A (en) | 2009-12-31 |
| JP2002506818A (ja) | 2002-03-05 |
| UY25436A1 (es) | 2001-10-25 |
| AR018113A1 (es) | 2001-10-31 |
| AU1591699A (en) | 1999-10-11 |
| SV1999000026A (es) | 2000-01-18 |
| KR20010041916A (ko) | 2001-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
| GB9801690D0 (en) | Therapeutic agents | |
| NO996269L (no) | Kinolin-indol antimikrobielle midler, samt anvendelse og blandinger derav | |
| GB2392154B (en) | Protein Kinase Inhibitors | |
| IL135921A (en) | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity | |
| NO934719D0 (no) | Hemmere av HIV-protease som er nyttige for behandling av AIDS | |
| NO955256D0 (no) | Fenylheterosykluser som syklooksygenase-2-inhibitorer | |
| DE60329316D1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| AP2001002318A0 (en) | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | |
| NZ526913A (en) | Inhibitors of cruzipain and other cysteine proteases | |
| FI935777A0 (fi) | Inhibitorer foer HIV-proteas anvaendbara vid behandling av AIDS | |
| DE69808326D1 (de) | Azetidinonderivate zur behandlung von hcmv entzündungen | |
| NZ505994A (en) | Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases | |
| ATE289204T1 (de) | Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie | |
| DK0604186T3 (da) | HIV-proteaseinhibitorer, som er egnede til behandling af AIDS | |
| DE60005517D1 (de) | Kaliumkanal-blockierende mittel | |
| BR9606429A (pt) | Composto composição e processo para tratamento de disfunção mediada por uPar- ou uPa- | |
| MXPA03000337A (es) | Inhibidores de trombina que comprenden un grupo aminoisoquinolina. | |
| SE9704770D0 (sv) | New use | |
| SE0102058D0 (sv) | New Salts II | |
| TW349864B (en) | Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders | |
| MY136928A (en) | New isoquinoline compounds, a process for their preparation and pharmaceutical composition containing them | |
| SE0004827D0 (sv) | Therapeutic compounds | |
| AU6902800A (en) | Pyridomorphinans and use thereof | |
| NZ531109A (en) | New mandelic acid derivatives and their use as thrombin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed |